Mitsubishi Tanabe Pharma contribute funding to
Global Health Innovative Technology Fund

Osaka, Japan, June 6, 2016—Mitsubishi Tanabe Pharma Corporation (President and Representative Director: Masayuki Mitsuka) has endorsed the objectives of the Global Health Innovative Technology Fund (GHIT Fund) and has decided to participate in the GHIT Fund’s new candidate compound discovery program.

The GHIT Fund is a public-private partnership, originating in Japan, that advances the discovery of new drugs for infectious diseases that burden the developing world, such as malaria, tuberculosis, and neglected tropical diseases (NTDs). The GHIT Fund aims to bolster Japan’s international contribution to global health through new drug R&D capabilities that leverage the advanced scientific and technical knowledge of Japanese pharmaceutical companies and other institutions.

By funding to GHIT Fund, Mitsubishi Tanabe Pharma will be able to contribute to the treatment of infectious diseases that burden the developing world. Accordingly, the Company decided to provide 20 million yen over the coming two years.

Mitsubishi Tanabe Pharma also provided its original pharmaceutical compound library (50,000 compounds) to Medicine for Malaria Venture (MMV), a screening institution that focuses on the discovery of anti-malaria drugs, via GHIT Fund in May 2015, and screening joint research have been proceeding to target the discovery of new anti-malaria drug candidate compounds that overcome the problem of resistance to existing anti-malaria drugs.

Through participation in the GHIT Fund, Mitsubishi Tanabe Pharma will contribute to the treatment of infectious diseases in the developing world.

〈〈For Details, Contact the Following Section〉〉
Corporate Communications Department
Tel +81-6-6205-5211